Fig. 5

Immunochemical characterization of TrxZnT8 from IB. a Dose–response curves for a pool of 5 ZnT8A RBA positive type 1 diabetic patient sera for different concentrations of TrxZnT8 from ISF (closed circle, dotted line) and TrxZnT8 from IB (open circle, solid line). b Dose–response curves for six ZnT8A RBA positive type 1 diabetic patient sera incubated with different concentrations of TrxZnT8 from IB. Each curve includes best-fit values from the log (inhibitor) vs. response–variable slope (four parameters) equation: correlation coefficient data (R²), IC₅₀ values and approximation to the affinity constant of ZnT8A (K_a) calculated as the inverse of IC₅₀. c Inhibition capacity of TrxZnT8 assessed in 33 ZnT8A RBA positive type 1 diabetic patient sera in the absence (B) or presence (C) of TrxZnT8. Twenty control sera were used in order to set a cut-off value (A). The binding was expressed as SDs, and the dotted line represents the cut-off value